Insulin Treatment of Patients with Diabetes and the Problem of Weight Gain: What Do You Need to Know as a Diabetes Nurse Educator?

10.5580/1ba5 ◽  
2007 ◽  
Vol 9 (1) ◽  
Keyword(s):  
Weight Gain ◽  
Insulin Treatment ◽  
Nurse Educator ◽  
Diabetes Nurse Educator ◽  
Patients With Diabetes

The Impact of a Diabetes Nurse Educator on Nurses' Knowledge of Diabetes and Nursing Interventions in a Home Care Setting

1994 ◽  
Vol 20 (1) ◽  
pp. 49-53 ◽  
Author(s):  
Carolyn E. Adams ◽  
David L. Cook
Keyword(s):  
Home Health Care ◽  
Nursing Care ◽  
Basic Knowledge ◽  
Nurse Educator ◽  
Nursing Interventions ◽  
Diabetes Nurse Educator ◽  
Patients With Diabetes ◽  
The Impact ◽  
Nurse Knowledge ◽  
Nurses Knowledge

The purpose of this study was to compare nurses' knowledge of diabetes and nursing interventions in a home health care agency (HHCA) that employed a diabetes nurse educator (DNE) and an agency that did not employ a DNE. Nurse knowledge of diabetes mellitus was measured using the Ditibetes: Basic Knowledge Test (DBKT). Nursing care interventions for patients with diabetes were measured using a researcher-developed tool, the Nursing Care Intervention Tool (NCIT). The data analysis showed that the nurses in the agency with the diabetes nurse educator were significantly more knowledgeable about diabetes. The data also showed that the nurses in the HHCA with a diabetes nurse educator provided a significantly higher standard of patient care than the nurses in the agency without a diabetes nurse educator.

scholarly journals Lack of association between either outpatient or inpatient glycemic control and COVID-19 illness severity or mortality in patients with diabetes

2021 ◽  
Vol 9 (1) ◽  
pp. e002203
Author(s):  
Paras B Mehta ◽  
Michael A Kohn ◽  
Suneil K Koliwad ◽  
Robert J Rushakoff
Keyword(s):  
Glycemic Control ◽  
Insulin Treatment ◽  
Insulin Level ◽  
Illness Severity ◽  
Icu Admission ◽  
Patients With Diabetes ◽  
Design And Methods ◽  
Insulin Use ◽  
Average Glucose ◽  
Ventilator Requirement

IntroductionTo evaluate whether outpatient insulin treatment, hemoglobin A1c (HbA1c), glucose on admission, or glycemic control during hospitalization is associated with SARS-CoV-2 (COVID-19) illness severity or mortality in hospitalized patients with diabetes mellitus (DM) in a geographical region with low COVID-19 prevalence.Research design and methodsA single-center retrospective study of patients hospitalized with COVID-19 from January 1 through August 31, 2020 to evaluate whether outpatient insulin use, HbA1c, glucose on admission, or average glucose during admission was associated with intensive care unit (ICU) admission, mechanical ventilation (ventilator) requirement, or mortality.ResultsAmong 111 patients with DM, 48 (43.2%) were on outpatient insulin and the average HbA1c was 8.1% (65 mmol/mol). The average glucose on admission was 187.0±102.94 mg/dL and the average glucose during hospitalization was 173.4±39.8 mg/dL. Use of outpatient insulin, level of HbA1c, glucose on admission, or average glucose during hospitalization was not associated with ICU admission, ventilator requirement, or mortality among patients with COVID-19 and DM.ConclusionsOur findings in a region with relatively low COVID-19 prevalence suggest that neither outpatient glycemic control, glucose on admission, or inpatient glycemic control is predictive of illness severity or mortality in patients with DM hospitalized with COVID-19.

1075-P: Acute and Chronic Glucose Control in Critically Ill Patients with Diabetes: Impact of Prior Insulin Treatment

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 1075-P
Author(s):  
JAMES S. KRINSLEY ◽  
PETER R. RULE ◽  
JEAN-CHARLES PREISER ◽  
GREG ROBERTS ◽  
SHEHROSE CHAUDRY ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Glucose Control ◽  
Insulin Treatment ◽  
Patients With Diabetes

Abstract 13242: Insulin Treated Patients With Diabetes Derive Reduction in Mortality From Cardiac Resynchronization Therapy - Results From the Madit-Crt in Trial Experience

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Barbara Szepietowska ◽  
Valentina Kutyifa ◽  
Martin H Ruwald ◽  
Scott D Solomon ◽  
Anne-Christine H Ruwald ◽  
...  
Keyword(s):  
Cardiac Resynchronization Therapy ◽  
Risk Reduction ◽  
Insulin Treatment ◽  
Cardiac Resynchronization ◽  
Reverse Remodeling ◽  
Diabetic Patients ◽  
Resynchronization Therapy ◽  
All Cause Mortality ◽  
Patients With Diabetes

Methods: We aimed to analyze the risk for death and HF and the effect of CRT on HF/death in diabetic patients with or without insulin treatment compared to none diabetic population. The study comprised 1278 patients with left bundle branch block in the MADIT-CRT trial with an average follow-up of 3.3y. We used time dependent survival analysis and Cox proportional hazards regression method. Results: In ICD arm patients with diabetes receiving insulin treatment had 2.4-fold higher risk of all-cause mortality (p=0.008), and 2.2-fold higher risk of HF (p<0.001) when compared to non diabetic patients, and 2.8-fold higher risk of death (p=0.01), and 1.6-fold higher risk of HF (p=0.06) when compared to patients with diabetes not treated with insulin. Treatment with CRT-D was associated with a significant 75% risk reduction in all-cause mortality (hazard ratio [HR ] 0.25; 95% confidence interval [CI]: 0.08-0.77; p=0.016) in patients with diabetes receiving insulin. Noteworthy, during the 3-year follow-up, reduction in all-cause mortality was not observed in patients not treated with insulin or in patients with no diabetes (interaction p-value=0.038). Significant risk reduction in HF and in HF/death after CRT treatment was observed across all three investigated groups. There were not significant differences in left ventricular reverse remodeling after CRT-D among diabetic patients with or without insulin treatment compared to the nondiabetic population. Conclusions: Patients with insulin treated diabetes derive significant reduction in mortality and heart failure after implantation of cardiac resynchronization therapy. Patients with diabetes and no insulin and patient without diabetes benefit from CRT by reduction of HF events.

INSULIN ANTIBODY FORMATION

1972 ◽  
Vol 71 (1) ◽  
pp. 126-140 ◽  
Author(s):  
O. Ortved Andersen
Keyword(s):  
Antibody Titre ◽  
Antibody Formation ◽  
Insulin Treatment ◽  
Maximum Level ◽  
Close Correlation ◽  
Porcine Insulin ◽  
Insulin Dosage ◽  
Insulin Preparation ◽  
Patients With Diabetes ◽  
Observation Period

ABSTRACT The investigation shows that in a group of fifty-one patients with diabetes mellitus treated with pure porcine insulin preparation, administered as crystal suspension of protamin-insulin, 76 per cent formed antibodies reacting with insulin. None of the patients in the observation period developed insulin resistance. No sex difference was demonstrated in the antibody formation, similarly, it was not possible to demonstrate a stimulation or accentuation in the antibody formation in connection with catarrhal infections. It was demonstrated that younger patients formed more antibodies than the older patients. Furthermore, a correlation was demonstrated between the antibody titre and the insulin dosage/kg weight. With the method used it was possible to demonstrate antibodies after 1–3 months of insulin treatment. The antibody titre attained a maximum level after insulin treatment for 4–9 months, after which it remained unchanged, probably as a consequence of afferent enhancement. It was found that the magnitude of the antibody titre was probably secondary to the size of the insulin dosage, and that because of the close correlation between regulation and insulin dosage, the influence of inadequate regulation could not be excluded. On the other hand, the magnitude of the antibody titre seemed to be without any importance for the regulation of diabetes, and in non-resistant diabetics to be without importance in determining the size of the insulin dosage.

Sign in / Sign up

Export Citation Format

Share Document